Who is closest to reversing aging?
In our longevity market deck, you will find everything you need to understand the market
SUMMARY
Life Biosciences is currently closest to reversing aging because it is the only private startup testing direct epigenetic rejuvenation in a human.
That lead is narrower than it sounds. ER-100 is being tested in one eye and in a small Phase 1 study, so even a successful result would prove local tissue rejuvenation rather than whole-body age reversal.
Rubedo Life Sciences has the strongest disclosed human efficacy result. Its early skin data are more clinically tangible than a change in a biological-age clock, although the analysis remains small, preliminary and company-reported.
NewLimit is the most credible threat to Life. Its liver program is still preclinical, but it combines temporary reprogramming, a scalable delivery route and roughly three times as much disclosed capital.
Retro Biosciences has assembled the broadest pipeline and already has a drug in Phase 1. The catch is that its lead program targets autophagy in Alzheimer’s disease rather than directly resetting cellular age.
Altos Labs leads the field in money and scientific depth, not observable translation. Several billion dollars have not yet produced a publicly named candidate, indication or clinical timetable.
The animal evidence points in two directions. Rejuvenate Bio has the most dramatic published lifespan result, while Life has the cleaner chain from mouse and primate experiments to a regulated human product.
Local rejuvenation is moving faster than systemic rejuvenation because delivery and safety are easier to control. Nobody has shown that reprogramming can be distributed across a large organ—or the whole body—without disrupting cell identity or creating unacceptable risk.
No company has customers in the normal commercial sense. Trial sites, manufacturing partners, investors and research collaborations show development progress, but not repeat demand, reimbursement or patient revenue.
The ranking could change quickly. A functional result from Life, replicated efficacy from Rubedo, safe liver rejuvenation from NewLimit or a credible candidate disclosure from Altos would be enough to reorder the leading group.
This market map, featured in our longevity market deck, highlights top companies and startups in the longevity market
Which startups are really trying to reverse aging?
The serious startup race to reverse aging currently comes down to eight private biotechs, and only three have placed any aging-biology drug into human trials.
We include companies trying to reset cellular age, restore youthful cell function, replace aged cell populations or remove a well-defined driver of aging. That gives us Life Biosciences, NewLimit, Altos Labs, Retro Biosciences, Rubedo Life Sciences, Turn Biotechnologies, Rejuvenate Bio and Shift Bioscience.
We leave out supplement brands, longevity clinics, biological-age testing companies and general preventive-health platforms. We also exclude public biotechs such as BioAge Labs, Unity Biotechnology and Longeveron because this comparison is about private startups. Calico sits outside the group as a long-established Alphabet research subsidiary. Loyal works on lifespan drugs for dogs, while Cambrian mainly builds a portfolio of separate aging companies. Both are relevant to longevity, but neither is a direct peer here.
Private-company funding is messy, so the amounts below are best read as public minimums. NewLimit’s total includes the founders’ original $105 million commitment. Retro has announced a new financing without disclosing its size. Altos launched with $3 billion, and later reporting says its total funding may now be close to $6 billion.
| Startup | What it is developing | Publicly disclosed or reported funding |
|---|---|---|
| Altos Labs | Cellular rejuvenation programs across several tissues and disease areas | At least $3B; nearly $6B reported |
| NewLimit | Cell-specific epigenetic reprogramming for the liver, immune system and vasculature | About $755M including founder capital |
| Life Biosciences | Controlled OSK reprogramming, beginning with damaged retinal cells | About $230M |
| Retro Biosciences | Autophagy drugs, rejuvenated blood and brain cells, tissue reprogramming and AI-designed proteins | At least $180M plus an undisclosed new round |
| Rubedo Life Sciences | Drugs that selectively target pathological senescent and stressed cells | About $52M |
| Turn Biotechnologies | Transient mRNA reprogramming combined with targeted delivery | About $30M |
| Rejuvenate Bio | Gene therapies for age-related disease, including partial reprogramming research | About $25M |
| Shift Bioscience | AI-discovered rejuvenation genes designed to avoid pluripotency | $18M disclosed |
Is there a clear leader in aging reversal today?
Life Biosciences is currently ahead overall because it is alone in testing direct epigenetic rejuvenation in a human.
That lead is narrow and specific. Rubedo has the best disclosed early efficacy result in people. Retro has the broadest visible pipeline and already runs a Phase 1 program. NewLimit has far more capital than Life and plans to test a more scalable liver therapy in 2027. Altos has an unmatched research budget but still offers no public clinical candidate.
The competitive gap looks very different depending on the metric. On direct human reprogramming, Life stands alone. On fresh clinical efficacy, Rubedo leads. On capital available for development, Altos is at least 13 times larger than Life and may be more than 25 times larger. NewLimit has roughly 3.3 times Life’s disclosed funding but remains one full clinical stage behind it.
Life has earned first place, although nobody has enough human data to make that position secure.
If you want more recent data on this point, please see our latest longevity market report.
As this slide shows, and as featured in our longevity market deck, online search interest in longevity has been steadily increasing
Has any aging startup actually reversed aging in a human?
No aging startup has yet proved that a human tissue became younger and worked better because of treatment.
A credible human result needs more than a younger-looking molecular clock. We would want to see a biological change tied to the intended mechanism, a meaningful improvement in tissue function, acceptable safety and enough follow-up to show that the effect lasts. Whole-body claims would require evidence across several organs or a convincing change in healthspan, which is much further away.
Rubedo has reduced precancerous skin lesions in an early trial, but clearing damaged cells in one patch of skin does not establish broad rejuvenation. Life is measuring safety and visual function in its first small eye study, so efficacy remains unknown. Retro’s clinical candidate targets autophagy in Alzheimer’s disease rather than resetting cellular age.
Human testing has begun. Human age reversal remains unproven.
Which aging startup has the strongest human evidence right now?
Rubedo has the strongest disclosed human efficacy result in aging biotech, while Life Biosciences has reached the bigger direct age-reversal milestone.
Rubedo reported that RLS-1496 reduced actinic keratosis lesions by 46% after four weeks, compared with 11% on untreated control areas, in the first 18 of 24 patients evaluated. The company reported no serious adverse events, no treatment discontinuations and little local irritation. In its earlier randomized Phase 1 work, Rubedo also reported a 20% fall in epidermal thickness in treated psoriasis skin versus a 30% increase with vehicle.
Those numbers are clinically interesting because actinic keratoses are visible, countable precancerous lesions. They still come from preliminary company-reported analyses, and the four-week study was small. Rubedo says a larger Phase 2b dose-ranging study will begin later this year, which should provide a much cleaner test.
Life’s ER-100 study has a different purpose. The trial plans to enroll up to 18 people with glaucoma or non-arteritic anterior ischemic optic neuropathy and will focus first on safety, with several measures of visual function included. Retro’s RTR242 has also entered Phase 1, but the company has not released human efficacy data.
| Startup | Most advanced disclosed program | Human stage today | What the human evidence shows |
|---|---|---|---|
| Rubedo Life Sciences | RLS-1496 for actinic keratosis and inflammatory skin disease | Phase 1 completed; Phase 1b/2a preliminary data | 46% lesion reduction versus 11% on untreated areas in an early analysis |
| Life Biosciences | ER-100 for glaucoma and NAION | Phase 1 active | Safety testing has begun; efficacy remains unknown |
| Retro Biosciences | RTR242 for Alzheimer’s disease | Phase 1 | Human dosing underway; no efficacy result disclosed |
| NewLimit | Liver-cell reprogramming therapy | Preclinical | First human study planned for 2027 |
| Altos Labs | Undisclosed rejuvenation programs | Preclinical or undisclosed | No named clinical candidate |
| Turn Biotechnologies | Transient mRNA reprogramming programs | Preclinical | No human data |
| Rejuvenate Bio | Human and animal gene-therapy programs | Preclinical in humans | No human data |
| Shift Bioscience | SB000 and other rejuvenation targets | Cell-stage research | No human data |
This chart, featured in our longevity market deck, illustrates yearly VC funding for longevity startups
Why is Life Biosciences still closest to reversing aging?
Life Biosciences stays first because ER-100 is the only direct epigenetic-rejuvenation therapy being tested in a person.
ER-100 delivers OCT4, SOX2 and KLF4, usually shortened to OSK, to retinal ganglion cells. It leaves out MYC, the fourth classic Yamanaka factor and the factor most closely associated with uncontrolled cell growth. A doxycycline-controlled switch lets doctors turn OSK expression on for a limited period.
Life also has the cleanest path from mechanism to medicine. The underlying research restored youthful gene-expression and methylation patterns in mice, promoted optic-nerve regeneration and improved visual function. The company later reported visual recovery in non-human primates. It then completed the manufacturing, toxicology and regulatory work needed to open a US trial.
The choice of the eye makes the program safer and easier to test. Doctors can inject one eye, monitor it directly and limit exposure to the rest of the body. Retinal ganglion cells divide very little, which reduces some of the risks associated with pushing cells toward a more plastic state.
That choice also limits what success would prove. Restoring vision in an injured eye would be a major medical result, but it would tell us little about rejuvenating the liver, muscles, immune system or brain. Life leads after clearing the hardest development hurdle first. Systemic aging is still unsolved.
If you want more recent data on this point, please see our latest longevity market report.
Can NewLimit overtake Life Biosciences in aging reversal?
NewLimit is the strongest threat to Life Biosciences, and the gap could shrink sharply when its liver program reaches the clinic.
NewLimit has assembled about $755 million from its founders and outside investors: an initial $105 million commitment, a $40 million Series A, a $130 million Series B, a $45 million extension and a $435 million Series C. Its latest round valued the company at $3.1 billion. That gives NewLimit more than three times Life’s capital and enough money to run several organ-specific programs at once.
The development timeline has also moved much faster than management once expected. NewLimit previously discussed first-in-human work as late as 2030. It now plans to begin a study in alcohol-related liver disease in 2027 after identifying a clinic-ready candidate earlier than expected. Cutting roughly three years from the public timeline is more meaningful than the valuation jump.
The liver is a bold first target. Lipid nanoparticles naturally reach liver cells, so NewLimit can deliver temporary genetic instructions without installing a permanent switch. A successful liver therapy could address larger patient populations than an ocular gene therapy and create a reusable model for metabolic disease.
NewLimit still has to clear the part that breaks many promising biotechs: reproducible animal efficacy, toxicology, manufacturing and regulatory acceptance. On capital, NewLimit leads Life by more than three to one. On human evidence, Life still leads by an entire stage.
This chart, featured in our longevity market deck, looks at Function Health’s strategy in longevity
Is Retro Biosciences taking the smarter route to aging reversal?
Retro Biosciences currently has the broadest aging pipeline, but its first human drug targets autophagy rather than cellular age itself.
RTR242 is an oral small molecule intended to restart autophagic flux, the recycling process cells use to remove damaged proteins and other waste. Retro moved the program from indication selection to first-in-human testing in about 15 months. That pace shows real development skill, even though an Alzheimer’s trial will take time to produce a clear efficacy answer.
The rest of Retro’s pipeline covers several distinct bets. RTR888 uses lab-made microglial progenitors for brain disorders. RTR890 aims to create rejuvenated blood-forming stem cells. Separate AAV programs target osteoarthritis and age-related hearing loss through tissue reprogramming. Retro also has an AI protein-design platform and an internal cell-therapy manufacturing facility.
Retro has built the broadest portfolio, but its most advanced program still targets one hallmark of aging rather than resetting cellular age.
Is Altos Labs secretly ahead in reversing aging?
Altos Labs may have the best research machine in longevity, yet the public evidence still places it behind four smaller startups.
Altos began with $3 billion, and The Wall Street Journal now reports that the company has raised nearly twice that amount. It has recruited prominent researchers in reprogramming, stress resilience, epigenetics, computation and drug development. It also hired Joan Mannick as chief medical officer and head of product development, launched an Institute of Computation and acquired senescence-focused Dorian Therapeutics.
Altos’s recent hires and acquisition show a stronger push toward products. We still have no named candidate, disease indication, trial registration or expected first dose. After more than four years and several billion dollars, that gap is too important to wave away.
Altos could have advanced programs behind closed doors, but secrecy cannot count as evidence of leadership. The company has the highest ceiling, the deepest bench and the longest financial runway. It will move up as soon as it shows a therapy that is close to patients. Until then, companies producing observable clinical milestones deserve the higher positions.
If you want more recent data on this point, please see our latest longevity market report.
This chart, featured in our longevity market deck, illustrates yearly funding for longevity startups
Which aging-reversal startup has the strongest animal evidence?
Life Biosciences has the best animal-to-human chain, while Rejuvenate Bio owns the most dramatic published lifespan result.
Life’s program progressed from old and injured mice to non-human primates using the same broad ocular logic now being tested clinically. The mouse work linked OSK treatment to optic-nerve regeneration, better visual function and younger molecular patterns. The primate data added a species with eyes and immune responses closer to humans.
Rejuvenate Bio produced the more striking lifespan headline. Researchers gave very old male mice an inducible systemic OSK therapy and reported a 109% increase in median remaining lifespan, along with better frailty scores. Because treatment started near the end of life, the result means the treated animals lived roughly twice as long from that late starting point. Their total lifespan did not double.
The Rejuvenate study was small and needs replication across larger groups, female animals and independent laboratories. Its commercial pipeline has also leaned toward liver-directed gene therapies and companion-animal programs. A recent $6 million financing and Merck Animal Health collaboration strengthen the veterinary route more than the direct human-reprogramming route.
We give Life the edge. Rejuvenate has a provocative organism-level result; Life has connected its animal work to an actual human product.
Which aging startup has the safest reprogramming and delivery system?
Life Biosciences has the safest-looking system for one eye, and nobody has solved safe rejuvenation across the body.
Life reduces risk through local AAV2 delivery, three reprogramming factors instead of four and a drug-controlled on-and-off switch. The setup lets doctors limit both the location and duration of reprogramming. Its safety advantage is real within ophthalmology, although the first trial must still show that the system behaves as intended in people.
NewLimit is pursuing a different safety design. It searches for cell-specific factor combinations and plans to deliver temporary instructions with lipid nanoparticles. Transient expression should reduce the danger of uncontrolled long-term reprogramming, and the liver is already a proven destination for this delivery technology. The trade-off is that repeated dosing may be necessary.
Turn also favors transient mRNA and has added microvesicle delivery through its acquisition of Vesigen’s ARMM technology. Shift is looking for single genes such as SB000 that can improve cellular age measures without activating pluripotency. Both ideas could ultimately prove safer than canonical Yamanaka factors, but neither has enough in-vivo evidence to win the comparison today.
The field has solved local delivery better than systemic delivery. Whole-body rejuvenation would require exceptional cell selectivity, careful dose control and proof that treated cells keep their identity. No startup has demonstrated all three.
This chart, featured in our longevity market deck, compares the main business model options for longevity clinics
Which aging startup could scale into a real medicine and find customers?
NewLimit has the most scalable direct-reprogramming design, Retro’s oral autophagy drug is the easiest to distribute, and no aging-reversal startup has real customers yet.
Life’s first product fits an existing medical workflow. Ophthalmologists already inject therapies into the eye, and a one-time treatment could support a high price if it restores lost vision. Viral-vector manufacturing remains expensive, and the same dose architecture becomes much harder when the target is a large organ.
NewLimit can draw on the industrial base created for mRNA and lipid-nanoparticle medicines. Temporary payloads are easier to modify than permanent gene therapies, and liver delivery is relatively efficient. If NewLimit can reuse the same discovery, formulation and manufacturing system across several liver diseases, its economics should improve with each program.
Retro’s small molecule has the clearest mass-market route because pills can be manufactured cheaply and prescribed without a specialist procedure. Its cell-replacement programs sit at the expensive end of the spectrum, with collection, manufacturing, conditioning and transplantation required for each patient. The internal cGMP facility gives Retro more control but cannot make those steps disappear.
No company has published usable pricing, payback or manufacturing-cost data. The delivery models are all we can compare for now, and they favor NewLimit for direct reprogramming and Retro for simple distribution.
Life has active trial sites, an external manufacturing relationship with Forge Biologics and enough new financing to fund operations into the second half of 2027. Rubedo has moved from an initial human study into a follow-on trial and plans a larger Phase 2b study. Those are the closest equivalents to commercial progress in this market.
NewLimit has attracted Eli Lilly Ventures, but an investment is weaker than a licensing deal or development partnership. Retro works with the Murdoch Children’s Research Institute and has built internal manufacturing. Rejuvenate’s collaboration with Merck Animal Health is commercially relevant, although it mainly advances therapies for companion animals. Turn has licensed technology to HanAll Biopharma and assembled delivery assets through acquisition.
Pilots, investor participation and research collaborations should not be presented as customer demand. Nobody has shown repeat orders, reimbursement, hospital adoption or patient revenue. The entire aging-reversal market remains pre-commercial.
Which aging startup is getting the most from its funding?
Rubedo has turned the least capital into the most human efficacy data, with Life Biosciences close behind on a much harder gene-therapy program.
Capital efficiency cannot be reduced to funding divided by trial phase because a topical cream costs far less to develop than an ocular gene therapy or a manufactured cell product. Even with that caveat, the spread is too large to ignore. Rubedo reached preliminary controlled human efficacy with about $52 million. Life opened a first-in-class gene-therapy study with roughly $230 million. NewLimit has about $755 million and remains preclinical, while Altos has spent years operating on a multibillion-dollar budget without revealing a candidate.
Retro sits in the middle. At least $180 million produced one Phase 1 small molecule, several preclinical programs, a 90-plus-person team and an internal manufacturing facility. Rejuvenate has generated unusually interesting mouse data and veterinary partnerships with about $25 million, but its human translation remains limited.
| Startup | Approximate funding | Best disclosed development result | Our capital-efficiency view |
|---|---|---|---|
| Rubedo Life Sciences | $52M | Preliminary controlled human efficacy | Best result per dollar so far |
| Life Biosciences | $230M | First direct reprogramming trial | Strong for a gene-therapy platform |
| Retro Biosciences | $180M plus undisclosed new funding | Phase 1 drug and broad pipeline | Solid, with substantial infrastructure built |
| Rejuvenate Bio | $25M | Published lifespan and frailty result in old mice | Strong animal output, slow human translation |
| Turn Biotechnologies | $30M | Preclinical platform and licensing activity | Too early for a firm judgment |
| Shift Bioscience | $18M | Cell-stage rejuvenation targets | Too early for a firm judgment |
| NewLimit | $755M | Clinic-ready liver candidate; trial planned | Expensive, but development has accelerated sharply |
| Altos Labs | $3B to nearly $6B reported | No public clinical candidate | Weakest visible translation per dollar |
If you want more recent data on this point, please see our latest longevity market report.
This chart, featured in our longevity market deck, illustrates how revenue is distributed across customer segments in the longevity market
Which aging startup is hardest to copy?
Life Biosciences is currently the hardest aging startup to copy in the clinic, while NewLimit may be building the more valuable long-term data advantage.
Life has licensed intellectual property around therapeutic OSK use and is accumulating manufacturing, toxicology, primate and regulatory know-how around a real product. That combination is harder to copy than the published reprogramming concept alone. Every month of clinical experience will add information that a later entrant cannot purchase instantly.
NewLimit repeatedly designs factor combinations, tests thousands of them and feeds the results back into its models. If that process produces different minimal payloads for liver, immune and vascular cells, its private perturbation dataset could become the field’s strongest discovery asset. The advantage will only become convincing when the platform produces treatments that work in animals and people.
Altos has a different advantage: money, talent and internal data generated across several institutes. Those resources are formidable, although scientists can move and foundational biology spreads through publications. Altos still needs protectable candidates and delivery systems.
Rubedo’s protection comes from its map of pathological senescent-cell subtypes and compounds that target them selectively. Turn combines payload and delivery patents, while Shift is building intellectual property around non-Yamanaka rejuvenation genes.
Which aging startups are moving fastest right now?
Life is moving fastest in the clinic, NewLimit has accelerated its development timeline the most, and Rubedo has produced the freshest efficacy result.
Life moved from FDA clearance to an active study and raised $80 million to carry the program through its early clinical work. NewLimit brought its first planned trial forward from around 2030 to 2027, added a vascular program and closed one of the largest private biotech rounds of the year. Rubedo followed an initial safety study with a measurable lesion result and is preparing a larger dose-ranging trial.
Retro also deserves a place in the leading group. It moved RTR242 into Phase 1 in roughly 15 months, announced another financing and says additional first-in-human milestones are planned for 2026 and 2027. Rejuvenate added fresh capital and Merck Animal Health as a research partner, though that progress is concentrated in veterinary medicine.
Altos has added senior product-development leadership and broader computational capacity, but its momentum remains hard to measure without a candidate. Turn and Shift continue to build useful technology at a much earlier stage.
The four companies gaining the most ground are Life, NewLimit, Rubedo and Retro. Life has the most important clinical position, while NewLimit is moving fastest toward challenging it.
This chart, featured in our longevity market deck, shows how longevity plan technology has evolved over time
How much of the aging-reversal evidence can we really trust?
Life Biosciences has the easiest evidence to verify because its trial is publicly registered and its core animal work is peer-reviewed. Most rival performance claims still come from company announcements.
Rubedo’s lesion counts are concrete and include untreated comparison areas, which makes them more useful than a vague statement about improvement. The analysis remains preliminary, covers only the first 18 evaluable patients and has not yet appeared as a complete peer-reviewed paper. We treat it as promising human evidence rather than a settled efficacy result.
NewLimit publishes unusually detailed operating updates, yet the crucial animal safety and efficacy package behind its clinic-ready candidate remains private. Altos discloses even less. Retro shows a clear pipeline and clinical status, while detailed human results are still pending. Turn and Shift rely heavily on platform descriptions and early laboratory findings.
Funding figures are easier to verify than scientific performance, but even those can differ across databases because founder commitments, grants and extension rounds are counted differently. That is why we use ranges for Altos and Retro and describe the other totals as approximate.
What could change the aging-reversal ranking?
One convincing human result could reorder the top five because every current lead rests on early evidence.
Life would pull away if ER-100 proves safe and restores measurable visual function, especially if tissue samples or imaging also show the intended rejuvenation mechanism. Serious toxicity or no biological activity would remove its main advantage.
Rubedo could challenge for first place if the larger actinic keratosis study reproduces the early lesion reduction with strong controls, durable effects and tissue evidence showing that pathological senescent cells were selectively removed. The company would then have validated an aging mechanism in people, even though it would still be treating a localized disease.
NewLimit has the biggest opportunity to overturn the order. Safe liver-cell rejuvenation would show that direct reprogramming can work in a large internal organ using a scalable delivery system. Retro could also rise quickly if RTR242 produces a meaningful Alzheimer’s result and one of its reprogramming or cell-replacement programs reaches patients.
Altos needs one convincing candidate disclosure to re-enter the top group. Its resources make rapid progress possible once a program emerges. Rejuvenate would move up if independent teams reproduce its lifespan result or if the company returns systemic reprogramming to the center of its human pipeline.
In our longevity market deck, we identify pain points entrepreneurs should prioritize
Which startups are actually ahead in reversing aging?
Life Biosciences is currently closest to reversing aging, with Rubedo and NewLimit as the two strongest challengers for very different reasons.
Life ranks first because direct epigenetic rejuvenation has finally crossed into regulated human testing. Rubedo ranks second because it has the clearest early human efficacy result against an aging-related cell population. NewLimit ranks third because its liver program combines direct reprogramming, a scalable delivery route and enough capital to run a serious clinical campaign.
Retro takes fourth place. Its pipeline is broader and more clinically mature than NewLimit’s overall, but its lead human program does not directly reset cellular age. Altos remains fifth because several billion dollars and exceptional scientists cannot outweigh the absence of a public candidate. Rejuvenate follows on the strength of its old-mouse lifespan result. Turn and Shift have credible ideas, with too little animal and clinical evidence to rank higher.
The distance between first and third is smaller than the funding numbers suggest. Life leads NewLimit by one clinical stage, while NewLimit leads Life by more than threefold in capital and probably by more in systemic scalability. Rubedo could pass both if its early result survives a larger controlled study and expands beyond skin. For now, Life has the milestone that matters most.
| Rank | Startup | Why it ranks here now |
|---|---|---|
| 1 | Life Biosciences | Only direct epigenetic-rejuvenation therapy in human testing, backed by mouse and primate functional evidence |
| 2 | Rubedo Life Sciences | Strongest disclosed early human efficacy result against an aging-related cellular mechanism |
| 3 | NewLimit | Best-positioned direct challenger, with a clinic-ready liver program, scalable delivery and about $755M in capital |
| 4 | Retro Biosciences | Broadest visible aging pipeline, one Phase 1 drug and serious internal development infrastructure |
| 5 | Altos Labs | Unmatched resources and scientific depth, but no public clinical candidate despite years of work |
| 6 | Rejuvenate Bio | Most dramatic published old-mouse lifespan result, with limited progress toward human reprogramming |
| 7 | Turn Biotechnologies | Sensible transient mRNA and delivery strategy, still short on disclosed in-vivo validation |
| 8 | Shift Bioscience | Interesting non-Yamanaka target-discovery approach, with evidence still concentrated in cells |
If you want more recent data on this point, please see our latest longevity market report.
OUR METHODOLOGY
This analysis asks which private startup is closest to reversing aging in a medically meaningful way. We define progress as restoring younger cellular function, replacing aged cell populations or removing a well-defined driver of aging while producing measurable functional benefits and maintaining acceptable safety.
We compare eight private companies: Life Biosciences, NewLimit, Altos Labs, Retro Biosciences, Rubedo Life Sciences, Turn Biotechnologies, Rejuvenate Bio and Shift Bioscience. We exclude supplement companies, longevity clinics, biological-age testing businesses, general preventive-health platforms, public biotechs and companies whose primary role is building or financing a portfolio of separate longevity businesses.
The ranking is not based on a fixed score. We separately examined clinical progress, human efficacy evidence, the directness of each biological approach, animal-to-human translation, delivery and safety, scalability, commercial readiness, capital efficiency, defensibility, recent development speed and the reliability of the evidence.
We give the most weight to observable milestones: registered clinical trials, peer-reviewed studies, disclosed patient results, named candidates, regulatory progress and clearly documented financing. Company statements remain useful for recent pipeline updates, but we treat preliminary or unpublished claims more cautiously than registered trials and peer-reviewed results.
Funding totals are treated as approximate public minimums because private-company disclosures do not always distinguish founder commitments, equity rounds, extensions, grants and undisclosed financings. Funding can support development, but it does not substitute for a candidate, a clinical trial or a reproducible biological result.
Key sources include Life Biosciences’ clinical pipeline, ClinicalTrials.gov, Life Biosciences’ publications, NewLimit’s research and programs, NewLimit’s company updates, Altos Labs, Retro Biosciences, Rubedo Life Sciences, Turn Biotechnologies, Shift Bioscience and Rejuvenate Bio.
We also used PubMed and journals from Nature, Science and Cell Press for peer-reviewed research; SEC filings and company announcements for financing; FDA materials for regulatory context; and disclosures from Forge Biologics, Merck Animal Health, the Murdoch Children’s Research Institute and Eli Lilly Ventures for manufacturing, research and investment relationships. The Wall Street Journal’s reporting is used for the higher estimate of Altos Labs’ total funding.
This chart, featured in our longevity market deck, illustrates how revenue is distributed across Europe, Asia, North America, Africa, and South America in the longevity market
Related blog posts
- Which startup looks most promising in reversing cellular aging?
- Who is closest to a real anti-aging drug today?
- Has any longevity drug worked yet?
